Concourse Financial Group Securities, Inc. Zentalis Pharmaceuticals, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.56 Billion
- Q2 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 100 shares of ZNTL stock, worth $436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$436
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$60.9 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$37.3 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$24.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$21 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$19.6 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $248M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...